Newton K, Strasser A
Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia.
J Exp Med. 2000 Jan 3;191(1):195-200. doi: 10.1084/jem.191.1.195.
Ionizing radiation and cytotoxic drugs used in the treatment of cancer induce apoptosis in many cell types, including tumor cells. It has been reported that tumor cells treated with anticancer drugs increase surface expression of Fas ligand (FasL) and are killed by autocrine or paracrine apoptosis signaling through Fas (Friesen, C., I. Herr, P.H. Krammer, and K.-M. Debatin. 1996. Nat. Med. 2:574-577). We show that lymphocytes that cannot be killed by FasL, such as those from Fas-deficient lpr mice or transgenic mice expressing a dominant negative mutant of Fas-associated death domain protein (FADD/MORT1), are as sensitive as normal lymphocytes to killing by gamma radiation or the cytotoxic drugs cis-platin, doxorubicin, and etoposide. In contrast, p53 deficiency or constitutive expression of Bcl-2 markedly increased the resistance of lymphocytes to gamma radiation or anticancer drugs but had no effect on killing by FasL. Consistent with these observations, lpr and wild-type T cells both had a reduced capacity for mitogen-induced proliferation after drug treatment, whereas bcl-2 transgenic or p53-deficient T cells retained significant clonogenic potential. These results demonstrate that apoptosis induced by ionizing radiation or anticancer drugs requires p53 and is regulated by the Bcl-2 protein family but does not require signals transduced by Fas and FADD/MORT1.
用于癌症治疗的电离辐射和细胞毒性药物可诱导包括肿瘤细胞在内的多种细胞类型发生凋亡。据报道,用抗癌药物处理的肿瘤细胞会增加Fas配体(FasL)的表面表达,并通过Fas被自分泌或旁分泌凋亡信号杀死(弗里森,C.,I. 赫尔,P.H. 克拉默,和K.-M. 德巴廷。1996年。《自然医学》2:574 - 577)。我们发现,不能被FasL杀死的淋巴细胞,如来自Fas缺陷型lpr小鼠或表达Fas相关死亡结构域蛋白(FADD/MORT1)显性负突变体的转基因小鼠的淋巴细胞,对γ辐射或细胞毒性药物顺铂、阿霉素和依托泊苷的杀伤作用与正常淋巴细胞一样敏感。相比之下,p53缺陷或Bcl-2的组成型表达显著增加了淋巴细胞对γ辐射或抗癌药物的抗性,但对FasL介导的杀伤没有影响。与这些观察结果一致,lpr和野生型T细胞在药物处理后丝裂原诱导的增殖能力均降低,而bcl-2转基因或p53缺陷的T细胞保留了显著的克隆形成潜力。这些结果表明,电离辐射或抗癌药物诱导的凋亡需要p53,受Bcl-2蛋白家族调控,但不需要Fas和FADD/MORTI转导的信号。